Laura Dichtel is an Endocrinology/Metabolic physician affiliated with Massachusetts General Hospital. OpenAlex indexes 74 publications with 2,766 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Bul457
Boston, MA 021142621
Telephone
617-724-3614Registry record last updated 31 Jul 2015.
Clinical trials
- The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20241 payment
- Novo Nordisk IncProgram year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
84.5%l-Thyroxine37.1%Levothyroxine Sodium100%Part D≥11 patientsRecombinant Human Growth Hormone21.6%Norditropin Flexpro100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
15.5%Corticosteroid15.5%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2017–2023 per NIH RePORTER. The latest:
- Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets
Massachusetts General Hospital
FY2023$126,000R03DK129635 - Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets
Massachusetts General Hospital
FY2022$126,000R03DK129635 - The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Massachusetts General Hospital
FY2021$198,297K23DK113220
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- OR12-06 Development of a Novel Growth Hormone Receptor Antagonist Antibody for the Treatment of Acromegaly
Journal of the Endocrine Society
2025 - 6570 Treatment of Cushing’s With Levoketoconazole: A Case Series
Journal of the Endocrine Society
2024
Similar KOLs
Other experts from the same institution or the same specialty.
James Januzzi, MD
Massachusetts General Hospital
Maurizio Fava, MD
Massachusetts General Hospital
Steven Greenberg, MD
Massachusetts General Hospital
David Scadden, MD
Massachusetts General Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”